Walgreens Boots Alliance Dirección

Dirección controles de criterios 1/4

El CEO de Walgreens Boots Alliance es Tim Wentworth, nombrado en Oct 2023, tiene una permanencia de 1.08 años. posee directamente un 0.019% de las acciones de la empresa, con un valor de €1.27M. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 3.1 años, respectivamente.

Información clave

Tim Wentworth

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.1yrs
Participación del CEO	0.02%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	3.1yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Tim Wentworth (64 yo)

1.1yrs

Permanencia

Mr. Timothy C. Wentworth, also known as Tim, served as Director of Ushur, Inc. since February 2022. He served as the Chief Executive Officer of Evernorth at Evernorth Health, Inc. (formerly known as Expres...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stefano Pessina	Executive Chairman of the Board	12.6yrs	US$7.57m	0.096% € 6.5m
Manmohan Mahajan	Executive VP & Global CFO	1.3yrs	US$1.83m	0.048% € 3.3m
Ornella Barra	Chief Operating Officer of International	no data	US$5.43m	0.25% € 16.9m
Timothy Wentworth	CEO & Director	1.1yrs	sin datos	0.019% € 1.3m
Todd Heckman	Senior VP	1.3yrs	sin datos	0.0019% € 130.5k
Neal Sample	Executive VP & Chief Information Officer	less than a year	sin datos	0.0066% € 447.2k
Tiffany Kanaga	Vice President of Global Investor Relations	no data	sin datos	sin datos
Matthew D'Ambrosio	Senior VP and Global Chief Compliance & Ethics Officer	no data	sin datos	sin datos
Lanesha Minnix	Executive VP & Global Chief Legal Officer	less than a year	sin datos	sin datos
Elizabeth Burger	Executive VP & Chief Human Resources Officer	no data	sin datos	sin datos
Liyue Wu	Head of M&A - Asia	no data	sin datos	sin datos
Tracey Brown	Executive VP	3yrs	sin datos	0.0087% € 590.0k

1.3yrs

Permanencia media

53.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de W8AD no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Stefano Pessina	Executive Chairman of the Board	12.6yrs	US$7.57m	0.096% € 6.5m
Timothy Wentworth	CEO & Director	1.1yrs	sin datos	0.019% € 1.3m
Ginger Graham	Lead Independent Director	14.6yrs	US$366.85k	0.00025% € 17.0k
Valerie Jarrett	Independent Director	4.1yrs	US$300.00k	0.00052% € 35.3k
Nancy Schlichting	Independent Director	18.1yrs	US$319.97k	0.0024% € 166.5k
John Lederer	Independent Director	9.6yrs	US$315.00k	0.0058% € 392.9k
Bryan Hanson	Independent Director	2.1yrs	US$84.62k	0.0036% € 242.6k
Janice Babiak	Independent Director	12.6yrs	US$325.00k	0.00014% € 9.5k
William Shrank	Director	less than a year	sin datos	0.00041% € 27.9k
Inderpal Bhandari	Independent Director	2.2yrs	US$115.29k	0.00035% € 23.8k
Thomas Polen	Director	1.3yrs	US$14.13k	0.0019% € 129.8k
Robert Huffines	Independent Director	less than a year	sin datos	sin datos

3.1yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de W8AD se considera experimentada (3.1 años de antigüedad promedio).

Walgreens Boots Alliance Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

Walgreens Announces Executive Appointments

High number of new directors

High number of new directors

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

High number of new directors

Recent updates

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on December 12, 2024

Walgreens Boots Alliance, Inc. Expects to Close Approximately 1,200 Stores over the Next 3 Years with About 500 Targeted to Close in Fiscal 2025

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2025

Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

Saxena White P.A. Files New Securities Fraud Class Action Lawsuit Against Walgreens Boots Alliance, Inc. and Certain of its Executives

Walgreens Boots Alliance, Inc. to Report Q4, 2024 Results on Oct 15, 2024

Walgreens Announces Executive Appointments

Gross Law Firm Announces Lawsuit Against Walgreens Boots Alliance, Inc

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on September 12, 2024

Boots Chief Quits Reportedly After Walgreens' Sale Plan Stalls

Walgreens Boots Alliance, Inc. to Report Q3, 2024 Results on Jun 27, 2024

Walgreens Announces Launch of Walgreens Brand Naloxone HCI Nasal Spray

Walgreens Reportedly Contacts Potential Buyers for £7 Billion Boots Drugstore Chain

Second quarter dividend of US$0.25 announced

Second quarter dividend of US$0.25 announced

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on June 12, 2024

High number of new directors

New major risk - Financial position

High number of new directors

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

High number of new directors

Walgreens Boots Alliance, Inc. Announces Executive Changes

Upcoming dividend of US$0.25 per share at 4.4% yield

Walgreens Boots Alliance, Inc. Announces Executive Changes

High number of new directors

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Walgreens Reportedly Explores $4 Billion-Plus Sale of Shields Health

Walgreens Reportedly Explores $4 Billion-Plus Sale of Shields Health

First quarter 2024 earnings released: US$0.078 loss per share (vs US$4.31 loss in 1Q 2023)

The Shareholder Commons, Inc Files a Notice of Exempt Solicitation to Walgreens Boots Alliance, Inc

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Upcoming dividend of US$0.48 per share at 8.8% yield

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2023

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$3.57 loss per share (vs US$5.02 profit in FY 2022)

Walgreens Boots Alliance, Inc. Appoints Tim Wentworth as Chief Executive Officer, Effective October 23, 2023

Walgreens Boots Alliance, Inc.(NasdaqGS:WBA) dropped from S&P 100

Dicello Levitt Files Lawsuit Against Kenvue, Procter & Gamble, Glaxosmithkline, and Walgreens

Dicello Levitt Files Lawsuit Against Kenvue, Procter & Gamble, Glaxosmithkline, and Walgreens

Walgreens Boots Alliance, Inc. Announces CEO Changes

High number of new directors

Walgreens Boots Alliance, Inc. Announces Departure of James Kehoe as Executive Vice President

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on September 12, 2023

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire 120 pharmacies in Texas, Louisiana and Arkansas from Brookshire Grocery Company.

An unknown buyer acquired 6.004471% stake in Option Care Health, Inc. (NasdaqGS:OPCH) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for approximately $330 million.

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

CEO & Director recently bought €313k worth of stock

Second quarter 2023 earnings released: EPS: US$0.81 (vs US$1.02 in 2Q 2022)

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad